Monitor the Wietexperiment's potential expansion beyond the current 10 municipalities (covering 69 of 562 total Dutch coffee shops) and the September 2026 interim report's impact on Dutch cannabis policy. Track CanAdelaar's revenue and EBITDA growth in upcoming Cronos quarterly filings to assess earnout realization and integration success.
Price Chart
Executive Summary
Cronos Group completed its acquisition of CanAdelaar, the largest cannabis company in the Netherlands' adult-use pilot program (Wietexperiment), for a base purchase price of €57.5 million plus cash earnouts of 0.5x Normalized EBITDA in 2026 and 2027. The deal establishes Cronos as the market leader in Europe's largest adult-use cannabis market and provides a platform for its borderless product strategy. The base purchase price represents approximately 1.4x CanAdelaar's annualized net revenue and 2.9x its annualized Adjusted EBITDA based on 1H 2026 results.
Key Financial Metrics
Key Facts
- Base purchase price of €57.5 million, subject to closing and post-closing adjustments
- Contingent cash earnout of 0.5x CanAdelaar's Normalized EBITDA in 2026 and 2027
- CanAdelaar is the largest cannabis company in the Netherlands' Wietexperiment, supplying nearly all 69 participating coffee shops
- CanAdelaar operates a 540,000-square-foot greenhouse facility with annual cultivation yield of approximately 20,000 kg of dried flower
- CanAdelaar net revenue grew to €15.2M in 2024, €40.6M in twelve months ended Sep 30, 2025, and €41.6M annualized for six months ended Jun 30, 2026
- CanAdelaar Adjusted EBITDA of €6.9M in 2024, €24.2M in twelve months ended Sep 30, 2025, and €20.1M annualized for six months ended Jun 30, 2026
- Base purchase price represents ~1.4x net revenue and ~2.9x Adjusted EBITDA on annualized 1H 2026 basis
- CanAdelaar's existing management team will continue to lead the business post-acquisition
Financial Impact
€57.5 million base purchase price plus earnouts of 0.5x Normalized EBITDA for 2026 and 2027; CanAdelaar annualized net revenue of €41.6M and Adjusted EBITDA of €20.1M (1H 2026 annualized)
Risk Factors
- Wietexperiment is limited to 10 municipalities and does not include Amsterdam; expansion is uncertain
- CanAdelaar's Adjusted EBITDA declined from €24.2M (TTM Sep 2025) to €20.1M annualized (1H 2026) due to increased competition as all licensed producers are now participating
- Integration risks and regulatory/environmental indemnities provided by Ring International Holding AG
- Cannabis sector remains subject to evolving regulatory frameworks in the EU and Netherlands
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381478 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $3.20 $3.21 | ▲ +0.31% | ▲ +1.42% | $3.31 (+3.44%) |
Oct 15, 2026 11d ago | Press Release | $3.20 $3.21 | ▲ +0.31% | ▲ +1.42% | $3.31 (+3.44%) |
Aug 6, 2026 11w ago | 8-K | $3.07 $3.10 | ▲ +0.98% | ▲ +0.37% | $3.31 (+7.82%) |
Aug 6, 2026 11w ago | Press Release | $3.07 $3.10 | ▲ +0.98% | ▲ +0.37% | $3.31 (+7.82%) |
Jul 16, 2026 14w ago | Press Release | $2.75 | awaiting T+1 | — | $3.31 (+20.36%) |
Jun 16, 2026 18w ago | Press Release | $2.67 $2.71 | ▲ +1.50% | ▲ +0.72% | $3.31 (+23.97%) |
May 11, 2026 24w ago | 8-K | $2.75 $2.77 | ▲ +0.73% | ▲ +0.86% | $3.31 (+20.36%) |
Apr 20, 2026 27w ago | Press Release | $2.76 | awaiting T+1 | — | $3.31 (+19.93%) |
Feb 26, 2026 34w ago | 8-K | $2.67 $2.67 | · 0.00% | ▲ +0.45% | $3.31 (+23.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers